Real-world treatment persistence of four commonly prescribed biologic therapies for moderate to severe psoriasis in Australia

CONCLUSIONS: The nationally representative PBS dataset can provide real-world insights into the persistence on biologic therapies for psoriasis in Australia, where eligibility criteria for reimbursed treatment are stringent. Persistence is an indirect marker of sustained treatment effectiveness and tolerability. Both unadjusted and adjusted analyses found longer persistence for guselkumab compared to adalimumab, secukinumab or ustekinumab.PMID:37705180 | DOI:10.1111/ajd.14153
Source: The Australasian Journal of Dermatology - Category: Dermatology Authors: Source Type: research